Global pharmaceutical production surged in 2025 due to tariff-driven front-loading but is expected to slow as trade uncertainty, patent expirations, pricing pressure, and shifting industrial policy reshape the industry’s growth, investment, and supply chain strategies.
Global pharmaceutical production experienced a surge in 2025, driven by front-loading activity as manufacturers accelerated global output ahead of anticipated tariff actions from the U.S.
According to a new industry trends report from Atradius, global manufacturing output rose by 9.1% in real terms in 2025, marking a sharp deviation from trend growth. However, this acceleration is expected to unwind in 2026, with production growth expected to slow to just 1.6% as inventories begin to normalize and production readjusts in the first half of the year.
While the immediate impact of tariff threats has been muted through exemptions, negotiated tariff caps, and selective relief granted to major producers, downside risks still loom, especially if trade tensions re-escalate.
According to Atradius’ industry report, the pharmaceutical sector benefits from a high degree of structural resilience due to its products being essential to healthcare delivery, along with the products having reduced exposed to economic downturns.
Demand for medicines continues to remain relatively stable across economic cycles, supporting the industry’s consistent production and business performance, highlighting strong credit conditions across the sector, allowing companies to plan long-term investment despite periods of macroeconomic uncertainty.
Atradius notes several key growth drivers in the sector, including:
* Structural resilience: Pharmaceutical products have become essential and are less affected by economic downturns.
* Aging demographics: Demand for over the counter (OTC) medicines, generics and medicines for treating chronic diseases has increased from older generations in developed markets.
* Emerging markets: Healthcare system improvements and more disposable household income is increasing demand within the sector.
* Banks and investors: External funding drives and support pharmaceutical oR&D efforts.
In the industry report, Atradius outlines the industry’s structural and regulatory challenges that hold the potential to affect profitability and investment priorities in the coming decade.
According to Atradius’ report, the key pressures for the pharmaceutical industry include:
* Upcoming patent cliff: Over 15 high level patents are set to expire over the next decade, resulting in brand-name drug producers increasing R&D spending.
* Public health spending: Several governments are actively containing or cutting public healthcare costs which potentially could impact investments in the sector.
* Environmental challenges: Companies could see an increase in pressure from environmental activists highlighting issues and concerns, such as pharmaceutical residues contaminating water and soil.
In the Americas, U.S. output rose 5.2% in 2025 but is now projected at just 0.9% for 2026 and is being influenced by fading tariff effects and growing generic and biosimilar competition. Canada and Mexico have displayed stable, moderate growth.
In Asia Pacific, China’s production is expected to grow 6.6% in 2026 after a 3.6% increase in 2025, being supported by government policies promoting biopharmaceutical innovation.India’s output is forecast to rise 5.0%, underpinned by domestic manufacturing incentives and expanding healthcare access. Singapore and Southeast Asia remain robust, with Singapore at 7.2% and Vietnam leading at 8.2%, reflecting rising incomes and foreign and domestic investment.
Europe presents a more mixed picture, with Eurozone output having surged at 21.6% in 2025 due to tariff-driven front-loading but is set to contract 3.7% in 2026 as the effect unwinds. Ireland benefited the most, while the U.K.’s zero-tariff agreement with the U.S. mitigates immediate risk.
Longer-term challenges in the sector include slower clinical trial setup, regulatory complexity, and increasing competition from lower-cost production in China and the U.S. Forecast compound annual growth rates from 2025 to 2030 highlight the divergence between regions, with China 4.5%, U.S. 3.0%, and the EU and U.K. 2.2%, respectively.
